Evidence map›Paper›PMID 37943351›Full record

ArticleCardiovascular and interventional radiology2024

Recurrent Colorectal Liver Metastases: Upfront Local Treatment versus Neoadjuvant Systemic Therapy Followed by Local Treatment (COLLISION RELAPSE): Study Protocol of a Phase III Prospective Randomized Controlled Trial.

Madelon Dijkstra, Babette I Kuiper, Hannah H Schulz, Susan van der Lei, Robbert S Puijk, Danielle J W Vos, Florentine E F Timmer, Hester J Scheffer, Tineke E Buffart, M Petrousjka van den Tol and 5 more

Registry-linked trialOpen access · hybridAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular and interventional radiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05861505 (COLLISION RELAPSE Trial - Recurrent Colorectal Liver Metastases), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05861505 phase3recruitingnot on this map

COLLISION RELAPSE Trial - Recurrent Colorectal Liver Metastases: Repeat Local Treatment +/- Neoadjuvant Systemic Therapy - a Phase III Prospective Randomized Controlled Trial

TypeinterventionalSponsorAmsterdam UMC, location VUmcRan2023 to 2028Enrolled360ConditionsColorectal Cancer, Liver Metastases, Liver Metastasis Colon Cancer, Chemotherapy EffectArmsNeoadjuvant systemic therapy (CAPOX+/-B FOLFOX+/-B FOLFIRI+/-B), Repeat local treatment
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Madelon Dijkstra *Department of Radiology and Nuclear Medicine, Amsterdam UMC, Location VUmc, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. m.dijkstra3@amsterdamumc.nl.ORCID http://orcid.org/0000-0002-5740-321X
Babette I Kuiper *Department of Surgery, Amsterdam UMC, Location VUmc, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Hannah H SchulzDepartment of Radiology and Nuclear Medicine, Amsterdam UMC, Location VUmc, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
Susan van der LeiDepartment of Radiology and Nuclear Medicine, Amsterdam UMC, Location VUmc, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
Robbert S PuijkDepartment of Radiology and Nuclear Medicine, Amsterdam UMC, Location VUmc, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
Danielle J W VosDepartment of Radiology and Nuclear Medicine, Amsterdam UMC, Location VUmc, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
Florentine E F TimmerDepartment of Radiology and Nuclear Medicine, Amsterdam UMC, Location VUmc, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
Hester J SchefferDepartment of Radiology and Nuclear Medicine, Amsterdam UMC, Location VUmc, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
Tineke E BuffartDepartment of Medical Oncology, Amsterdam UMC, Location VUmc, Cancer Center Amsterdam, Amsterdam, The Netherlands.
M Petrousjka van den TolDepartment of Surgery, Medical Center Leeuwarden, Leeuwarden, The Netherlands.
Birgit I Lissenberg-WitteDepartment of Epidemiology and Data Science, Amsterdam University Medical Centers, Location VUmc, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Rutger-Jan SwijnenburgDepartment of Surgery, Amsterdam UMC, Location VUmc, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Kathelijn S Versteeg *Department of Medical Oncology, Amsterdam UMC, Location VUmc, Cancer Center Amsterdam, Amsterdam, The Netherlands.
Martijn R Meijerink *Department of Radiology and Nuclear Medicine, Amsterdam UMC, Location VUmc, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
COLLISION Trial Group
Cancer Center Amsterdam · NLAmsterdam University Medical Centers · NLAmsterdam Neuroscience · NLMedisch Centrum Leeuwarden · NLNoordwest Ziekenhuisgroep · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe objective of the COLLISION RELAPSE trial is to prove or disprove superiority of neoadjuvant systemic therapy followed by repeat local treatment (either thermal ablation and/or surgical resection), compared to repeat local treatment alone, in patients with at least one recurrent locally treatable CRLM within one year and no extrahepatic disease.

methodsA total of 360 patients will be included in this phase III, multicentre randomized controlled trial. The primary endpoint is overall survival. Secondary endpoints are distant progression-free survival, local tumour progression-free survival analysed per patient and per tumour, systemic therapy-related toxicity, procedural morbidity and mortality, length of hospital stay, pain assessment and quality of life, cost-effectiveness ratio and quality-adjusted life years. DISCUSSION: If the addition of neoadjuvant systemic therapy to repeat local treatment of CRLM proves to be superior compared to repeat local treatment alone, this may lead to a prolonged life expectancy and increased disease-free survival at the cost of possible systemic therapy-related side effects. LEVEL OF EVIDENCE: Level 1, phase III randomized controlled trial.

trial registrationNCT05861505. May 17, 2023.

Indexed as

Colorectal NeoplasmsLiver NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsClinical Trials, Phase III as TopicEquivalence Trials as TopicHumansMulticenter Studies as TopicNeoadjuvant TherapyProspective StudiesQuality of LifeRandomized Controlled Trials as TopicRecurrenceColorectal cancerColorectal liver metastases (CRLM)Neoadjuvant systemic therapyRandomized controlled trial (RCT)SurgeryThermal ablation

Identifiers

PMID37943351
PMCPMC10844349
OpenAlexW4388522889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.